Cargando…
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
Autores principales: | Mangia, Alessandra, Piazzolla, Valeria, Giannelli, Anna, Visaggi, Egidio, Minerva, Nicola, Palmieri, Vincenzo, Carraturo, Immacolata, Potenza, Domenico, Napoli, Nicola, Lauletta, Gianfranco, Tagarielli, Vincenzo, Santoro, Rosanna, Piccigallo, Ernesto, De Gioia, Sergio, Chimenti, Angelo, Cuccorese, Giuseppe, Metrangolo, Antonio, Mazzola, Michele, Agostinacchio, Ernesto, Mennea, Giuseppe, Sabbà, Carlo, Cela, Marina, Copetti, Massimiliano, Losappio, Ruggiero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760782/ https://www.ncbi.nlm.nih.gov/pubmed/31553772 http://dx.doi.org/10.1371/journal.pone.0223287 |
Ejemplares similares
-
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
por: Mangia, Alessandra, et al.
Publicado: (2019) -
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis
por: Mangia, Alessandra, et al.
Publicado: (2018) -
437 A TAILORED PROGRAM FOR SCREENING, IMPROVED ACCESS TO CARE, AND PRIORITIZATION OF TREATMENT FOR PWUD WITH CHRONIC HCV INFECTION.
por: Mangia, Alessandra, et al.
Publicado: (2021) -
Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy
por: Mangia, Alessandra, et al.
Publicado: (2021) -
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
por: Mangia, Alessandra, et al.
Publicado: (2019)